AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance

Fiscal 2022 Second Quarter Highlights

  • Net sales of $78.3 million increased 7.6% compared to the prior-year quarter
  • Med Tech growth of 36.4% and Med Device growth of 0.8% year over year
  • Gross margin of 51.8% declined 340 basis points year over year
  • GAAP loss per share of $0.21, and adjusted loss per share of $0.02
  • The Company commenced full market release of its AlphaVac Mechanical Thrombectomy device subsequent to quarter end

LATHAM, N.Y.--()--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the second quarter of fiscal year 2022, which ended November 30, 2021.

“We are pleased with our continued strong revenue growth as our team navigates this dynamic macro environment and manages through persistent COVID headwinds,” commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics. “Revenue growth this quarter was driven by our Med Tech platforms, particularly our atherectomy and thrombectomy portfolios. The ongoing disruptions from the COVID pandemic and resulting labor and supply chain headwinds led to a $4.0 million backlog at quarter end, impacting our gross margin and earnings. We have implemented measures to address these challenges. Our solid revenue growth and this backlog illustrate the strong demand for our products in the marketplace, and, despite these challenges, we remain firmly in investment mode. I am confident in our team’s ability to sustain the growth of our portfolio over time as we execute on our strategic plan to transform the company through investment in key growth technologies like our AlphaVac F22 mechanical thrombectomy system, which entered full market release in early December.”

Second Quarter 2022 Financial Results

Net sales for the second quarter of fiscal 2022 were $78.3 million, an increase of 7.6% compared to the prior-year quarter.

Foreign currency translation did not have a significant impact on the Company’s sales in the quarter.

Med Tech net sales were $18.9 million, a 36.4% increase from $13.8 million in the prior year period, while Med Device net sales were $59.4 million, an increase of 0.8% compared to $58.9 million in the prior year period. Med Tech includes the Auryon Peripheral Atherectomy platform, thrombectomy and the NanoKnife irreversible electroporation platform. The Company’s performance during the quarter was particularly impacted by increasing supply chain constraints, as well as headwinds driven by lower procedural volumes that impacted some of the Company’s product lines. Hospitals faced meaningful staffing challenges during the quarter, in addition to increased COVID-related restrictions.

  • Endovascular Therapies (formerly Vascular Interventions and Therapies) net sales were $39.7 million, an increase of 17.0%, compared to $33.9 million a year ago. Growth was driven by strength in our atherectomy and thrombectomy portfolios relative to the prior-year period. Auryon sales during the quarter were $6.3 million, as the Company continued to see sequential sales growth of this platform.
  • Oncology net sales were $13.6 million, a decrease of 9.3%, compared to $14.9 million in the prior-year period. The year-over-year decline was largely due to lower capital sales, partially offset by increased sales of disposables.
  • Vascular Access net sales were $25.1 million, an increase of 4.8%, compared to $23.9 million a year ago.

U.S. net sales in the second quarter of fiscal 2022 were $65.4 million, an increase of 7.7% from $60.7 million a year ago. International net sales were $12.9 million, an increase of 7.0%, compared to $12.1 million a year ago.

Gross margin for the second quarter of fiscal 2022 was 51.8%, a decrease of 340 basis points compared to the second quarter of fiscal 2021. During the quarter, gross margin was negatively impacted by macro forces including labor shortages and under absorption of fixed costs as well as increased expense for raw materials, labor, and freight. Gross margins were also impacted by startup costs related to Auryon and AlphaVac.

The Company recorded a net loss of $8.4 million, or a loss per share of $0.21, in the second quarter of fiscal 2022. This compares to a net loss of $4.3 million, or a loss per share of $0.11, a year ago.

Excluding the items shown in the non-GAAP reconciliation table below, adjusted net loss for the second quarter of fiscal 2022 was $0.9 million, and adjusted loss per share was $0.02, compared to adjusted net income in the prior-year period of $0.6 million and adjusted earnings per share of $0.01.

Adjusted EBITDA in the second quarter of fiscal 2022, excluding the items shown in the reconciliation table below, was $4.4 million, compared to $5.2 million in the second quarter of fiscal 2021.

In the second quarter of fiscal 2022, the Company generated $1.9 million in operating cash, had capital expenditures of $1.1 million and additions to Auryon placement and evaluation units of $2.7 million. As of November 30, 2021, the Company had $34.3 million in cash and cash equivalents compared to $35.5 million in cash and cash equivalents on August 31, 2021. The Company had debt outstanding of $25.0 million on November 30, 2021, compared to $25.0 million on August 31, 2021.

Six Months Financial Results

For the six months ended November 30, 2021:

  • Net sales were $155.3 million, an increase of 8.6%, compared to $143.0 million for the same period a year ago.
  • The Company’s net loss was $15.3 million, or a loss of $0.39 per share, compared to a net loss of $8.5 million, or a loss of $0.22 per share, a year ago.
  • Gross margin decreased 110 basis points to 52.0% from 53.1% a year ago.
  • Excluding the items shown in the non-GAAP reconciliation table, below, adjusted net loss was $1.7 million, with adjusted loss per share of $0.04, compared to adjusted net income and adjusted earnings per share of $1.2 million, and $0.03, respectively, a year ago.
  • Adjusted EBITDA, excluding the items shown in the reconciliation table below, was $8.0 million, compared to $9.6 million for the same period a year ago.

Reiterating Fiscal Year 2022 Revenue Guidance; Revising Gross Margin and Adjusted EPS Guidance

The Company continues to expect its fiscal year 2022 net sales to be in the range of $310 to $315 million. Gross margin is now expected to be in the range of 52.0% to 54.0%, a decrease from the Company’s prior guidance of 55.0%, as headwinds persist regarding labor shortages and inflationary pressures on raw materials and transportation. Due to the macroeconomic pressures on gross margin, as discussed above, the Company now expects adjusted earnings per share in the range of a loss of $0.02 to a gain of $0.02, below its prior guidance of a range of $0.00 to $0.05.

Conference Call

The Company's management will host a conference call today at 8:00 a.m. ET to discuss its second quarter results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13725681.

This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 11:00 a.m. ET on Thursday, January 6, 2022, until 11:59 p.m. ET on Thursday, January 13, 2022. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13725681.

Use of Non-GAAP Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported adjusted EBITDA, adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

About AngioDynamics, Inc.

AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products, and venous products. For more information, visit www.angiodynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," “projects”, "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation and labor shortages), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2021. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue and is similarly approved for commercialization in Canada, the European Union, and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED INCOME STATEMENTS

(in thousands, except per share data)

 

Three Months Ended

 

Six Months Ended

 

Nov 30, 2021

 

Nov 30, 2020

 

Nov 30, 2021

 

Nov 30, 2020

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Net sales

$

78,280

 

 

 

$

72,770

 

 

 

$

155,251

 

 

 

$

142,986

 

 

Cost of sales (exclusive of intangible amortization)

37,725

 

 

 

32,596

 

 

 

74,557

 

 

 

67,048

 

 

Gross profit

40,555

 

 

 

40,174

 

 

 

80,694

 

 

 

75,938

 

 

% of net sales

51.8

 

%

 

55.2

 

%

 

52.0

 

%

 

53.1

 

%

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

Research and development

8,199

 

 

 

9,712

 

 

 

15,593

 

 

 

18,721

 

 

Sales and marketing

23,606

 

 

 

20,174

 

 

 

48,052

 

 

 

37,879

 

 

General and administrative

9,678

 

 

 

9,219

 

 

 

18,621

 

 

 

17,776

 

 

Amortization of intangibles

4,889

 

 

 

4,593

 

 

 

9,710

 

 

 

9,546

 

 

Change in fair value of contingent consideration

609

 

 

 

184

 

 

 

804

 

 

 

(473

)

 

Acquisition, restructuring and other items, net

2,253

 

 

 

1,128

 

 

 

4,693

 

 

 

2,447

 

 

Total operating expenses

49,234

 

 

 

45,010

 

 

 

97,473

 

 

 

85,896

 

 

Operating loss

(8,679

)

 

 

(4,836

)

 

 

(16,779

)

 

 

(9,958

)

 

Interest expense, net

(174

)

 

 

(235

)

 

 

(330

)

 

 

(450

)

 

Other income (expense), net

(10

)

 

 

(102

)

 

 

(362

)

 

 

422

 

 

Total other expense, net

(184

)

 

 

(337

)

 

 

(692

)

 

 

(28

)

 

Loss before income tax benefit

(8,863

)

 

 

(5,173

)

 

 

(17,471

)

 

 

(9,986

)

 

Income tax benefit

(512

)

 

 

(905

)

 

 

(2,148

)

 

 

(1,450

)

 

Net loss

$

(8,351

)

 

 

$

(4,268

)

 

 

$

(15,323

)

 

 

$

(8,536

)

 

 

 

 

 

 

 

 

 

Loss per share

 

 

 

 

 

 

 

Basic

$

(0.21

)

 

 

$

(0.11

)

 

 

$

(0.39

)

 

 

$

(0.22

)

 

Diluted

$

(0.21

)

 

 

$

(0.11

)

 

 

$

(0.39

)

 

 

$

(0.22

)

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

 

 

 

 

 

Basic

39,053

 

 

 

38,327

 

 

 

38,893

 

 

 

38,242

 

 

Diluted

39,053

 

 

 

38,327

 

 

 

38,893

 

 

 

38,242

 

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION

(in thousands, except per share data)

Reconciliation of Net Loss to non-GAAP Adjusted Net Income (Loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

Nov 30, 2021

 

Nov 30, 2020

 

Nov 30, 2021

 

Nov 30, 2020

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(8,351

)

 

 

$

(4,268

)

 

 

$

(15,323

)

 

 

$

(8,536

)

 

 

 

 

 

 

 

 

 

Amortization of intangibles

4,889

 

 

 

4,593

 

 

 

9,710

 

 

 

9,546

 

 

Change in fair value of contingent consideration

609

 

 

 

184

 

 

 

804

 

 

 

(473

)

 

Acquisition, restructuring and other items, net (1)

2,253

 

 

 

1,128

 

 

 

4,693

 

 

 

2,447

 

 

Tax effect of non-GAAP items (2)

(256

)

 

 

(1,073

)

 

 

(1,627

)

 

 

(1,803

)

 

Adjusted net income (loss)

$

(856

)

 

 

$

564

 

 

 

$

(1,743

)

 

 

$

1,181

 

 

 

 

 

 

 

 

 

 

Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted Diluted Earnings (Loss) Per Share:

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

Nov 30, 2021

 

Nov 30, 2020

 

Nov 30, 2021

 

Nov 30, 2020

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Diluted loss per share

$

(0.21

)

 

 

$

(0.11

)

 

 

$

(0.39

)

 

 

$

(0.22

)

 

 

 

 

 

 

 

 

 

Amortization of intangibles

0.13

 

 

 

0.12

 

 

 

0.25

 

 

 

0.25

 

 

Change in fair value of contingent consideration

0.02

 

 

 

 

 

 

0.02

 

 

 

(0.01

)

 

Acquisition, restructuring and other items, net (1)

0.05

 

 

 

0.03

 

 

 

0.12

 

 

 

0.06

 

 

Tax effect of non-GAAP items (2)

(0.01

)

 

 

(0.03

)

 

 

(0.04

)

 

 

(0.05

)

 

Adjusted diluted earnings (loss) per share

$

(0.02

)

 

 

$

0.01

 

 

 

$

(0.04

)

 

 

$

0.03

 

 

 

 

 

 

 

 

 

 

Adjusted diluted sharecount (3)

39,053

 

 

38,473

 

 

38,893

 

 

38,503

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended November 30, 2021 and 2020.

(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION (Continued)

(in thousands, except per share data)

Reconciliation of Net Loss to Adjusted EBITDA:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

Nov 30, 2021

 

Nov 30, 2020

 

Nov 30, 2021

 

Nov 30, 2020

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(8,351

)

 

 

$

(4,268

)

 

 

$

(15,323

)

 

 

$

(8,536

)

 

 

 

 

 

 

 

 

 

Income tax benefit

(512

)

 

 

(905

)

 

 

(2,148

)

 

 

(1,450

)

 

Interest expense, net

174

 

 

 

235

 

 

 

330

 

 

 

450

 

 

Depreciation and amortization

7,240

 

 

 

6,397

 

 

 

14,199

 

 

 

12,936

 

 

Change in fair value of contingent consideration

609

 

 

 

184

 

 

 

804

 

 

 

(473

)

 

Stock based compensation

3,008

 

 

 

2,387

 

 

 

5,437

 

 

 

4,251

 

 

Acquisition, restructuring and other items, net (1)

2,253

 

 

 

1,128

 

 

 

4,693

 

 

 

2,447

 

 

Adjusted EBITDA

$

4,421

 

 

 

$

5,158

 

 

 

$

7,992

 

 

 

$

9,625

 

 

 

 

 

 

 

 

 

 

Per diluted share:

 

 

 

 

 

 

 

Adjusted EBITDA

$

0.11

 

 

 

$

0.13

 

 

 

$

0.21

 

 

 

$

0.25

 

 

 

 

 

 

 

 

 

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY

(in thousands)

 

Three Months Ended

 

Six Months Ended

 

Nov 30, 2021

 

Nov 30, 2020

 

% Growth

 

Currency Impact

 

Constant
Currency
Growth

 

Nov 30, 2021

 

Nov 30, 2020

 

% Growth

 

Currency Impact

 

Constant
Currency
Growth

 

 

 

 

 

 

 

 

 

 

 

(unaudited)

 

 

 

 

 

 

 

(unaudited)

 

 

 

 

 

 

Net Sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Med Tech

$

18,886

 

 

$

13,849

 

 

36.4%

 

 

 

 

 

$

36,504

 

 

$

24,335

 

 

50.0%

 

 

 

 

Med Device

59,394

 

 

58,921

 

 

0.8%

 

 

 

 

 

118,747

 

 

118,651

 

 

0.1%

 

 

 

 

 

$

78,280

 

 

$

72,770

 

 

7.6%

 

0.1%

 

7.7%

 

$

155,251

 

 

$

142,986

 

 

8.6%

 

0.4%

 

9.0%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Sales by Product Category

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Endovascular Therapies

$

39,660

 

 

$

33,900

 

 

17.0%

 

 

 

 

 

$

77,718

 

 

$

63,757

 

 

21.9%

 

 

 

 

Vascular Access

25,070

 

 

23,930

 

 

4.8%

 

 

 

 

 

50,026

 

 

52,035

 

 

(3.9)%

 

 

 

 

Oncology

13,550

 

 

14,940

 

 

(9.3)%

 

 

 

 

 

27,507

 

 

27,194

 

 

1.2%

 

 

 

 

 

$

78,280

 

 

$

72,770

 

 

7.6%

 

0.1%

 

7.7%

 

$

155,251

 

 

$

142,986

 

 

8.6%

 

0.4%

 

9.0%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Sales by Geography

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

$

65,350

 

 

$

60,684

 

 

7.7%

 

 

 

 

 

$

129,814

 

 

$

114,792

 

 

13.1%

 

 

 

 

International

12,930

 

 

12,086

 

 

7.0%

 

0.8%

 

7.8%

 

25,437

 

 

28,194

 

 

(9.8)%

 

2.0%

 

(7.8)%

 

$

78,280

 

 

$

72,770

 

 

7.6%

 

0.1%

 

7.7%

 

$

155,251

 

 

$

142,986

 

 

8.6%

 

0.4%

 

9.0%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands)

 

Nov 30, 2021

 

May 31, 2021

 

(unaudited)

 

(audited)

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

34,291

 

 

$

48,161

 

Accounts receivable, net

38,205

 

 

35,405

 

Inventories

48,183

 

 

48,614

 

Prepaid expenses and other

11,506

 

 

8,699

 

Total current assets

132,185

 

 

140,879

 

Property, plant and equipment, net

43,090

 

 

37,073

 

Other assets

12,119

 

 

13,193

 

Intangible assets, net

165,000

 

 

168,977

 

Goodwill

201,709

 

 

201,316

 

Total assets

$

554,103

 

 

$

561,438

 

Liabilities and stockholders' equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

24,191

 

 

$

19,630

 

Accrued liabilities

27,715

 

 

35,459

 

Other current liabilities

2,569

 

 

2,495

 

Total current liabilities

54,475

 

 

57,584

 

Long-term debt

25,000

 

 

20,000

 

Deferred income taxes

17,994

 

 

19,955

 

Contingent consideration

16,540

 

 

15,741

 

Other long-term liabilities

7,726

 

 

8,701

 

Total liabilities

121,735

 

 

121,981

 

Stockholders' equity

432,368

 

 

439,457

 

Total Liabilities and Stockholders' Equity

$

554,103

 

 

$

561,438

 

 

 

 

 

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

Three Months Ended

 

Six Months Ended

 

Nov 30, 2021

 

Nov 30, 2020

 

Nov 30, 2021

 

Nov 30, 2020

 

(unaudited)

 

(unaudited)

Cash flows from operating activities:

 

 

 

 

 

 

 

Net loss

$

(8,351

)

 

 

$

(4,268

)

 

 

$

(15,323

)

 

 

$

(8,536

)

 

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

7,279

 

 

 

6,436

 

 

 

14,276

 

 

 

13,013

 

 

Non-cash lease expense

607

 

 

 

599

 

 

 

1,209

 

 

 

1,265

 

 

Stock based compensation

3,008

 

 

 

2,387

 

 

 

5,437

 

 

 

4,251

 

 

Change in fair value of contingent consideration

609

 

 

 

184

 

 

 

804

 

 

 

(473

)

 

Deferred income taxes

(569

)

 

 

(933

)

 

 

(2,259

)

 

 

(1,553

)

 

Change in accounts receivable allowances

60

 

 

 

(431

)

 

 

16

 

 

 

29

 

 

Fixed and intangible asset impairments and disposals

67

 

 

 

90

 

 

 

97

 

 

 

180

 

 

Other

(32

)

 

 

202

 

 

 

(78

)

 

 

(230

)

 

Changes in operating assets and liabilities, net of acquisitions:

 

 

 

 

 

 

 

Accounts receivable

(2,886

)

 

 

425

 

 

 

(2,922

)

 

 

(2,281

)

 

Inventories

1,148

 

 

 

3,281

 

 

 

478

 

 

 

10,528

 

 

Prepaid expenses and other

(830

)

 

 

(2,764

)

 

 

(4,184

)

 

 

(6,323

)

 

Accounts payable, accrued and other liabilities

1,831

 

 

 

6,240

 

 

 

(4,514

)

 

 

(3,847

)

 

Net cash (used in) provided by operating activities

1,941

 

 

 

11,448

 

 

 

(6,963

)

 

 

6,023

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

Additions to property, plant and equipment

(1,131

)

 

 

(1,361

)

 

 

(2,152

)

 

 

(3,185

)

 

Additions to placement and evaluation units

(2,718

)

 

 

 

 

 

(7,189

)

 

 

 

 

Cash paid in acquisition

 

 

 

 

 

 

(3,600

)

 

 

 

 

Net cash used in investing activities

(3,849

)

 

 

(1,361

)

 

 

(12,941

)

 

 

(3,185

)

 

Cash flows from financing activities:

 

 

 

 

 

 

 

Proceeds from borrowings on long-term debt

 

 

 

 

 

 

5,000

 

 

 

 

 

Proceeds from exercise of stock options and employee stock purchase plan

942

 

 

 

(10

)

 

 

1,388

 

 

 

481

 

 

Net cash provided by financing activities

942

 

 

 

(10

)

 

 

6,388

 

 

 

481

 

 

Effect of exchange rate changes on cash and cash equivalents

(215

)

 

 

19

 

 

 

(354

)

 

 

271

 

 

(Decrease) increase in cash and cash equivalents

(1,181

)

 

 

10,096

 

 

 

(13,870

)

 

 

3,590

 

 

Cash and cash equivalents at beginning of period

35,472

 

 

 

47,929

 

 

 

48,161

 

 

 

54,435

 

 

Cash and cash equivalents at end of period

$

34,291

 

 

 

$

58,025

 

 

 

$

34,291

 

 

 

$

58,025

 

 

 

Contacts

Investor:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408

 

Contacts

Investor:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408